[Inhibition of monoamine oxidase and diamine oxidase by furazolidone (Furoxon). Pharmacologic and biochemical studies in man].
D006631:Amine Oxidase (Copper-Containing) / Q000037:antagonists & inhibitors*; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D001068:Feeding and Eating Disorders / Q000139:chemically induced; D005664:Furazolidone / Q000097:blood / Q000494:pharmacology*; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D007210:Indoleacetic Acids / Q000652:urine; D008333:Mandelic Acids / Q000652:urine; D005222:Mental Fatigue / Q000139:chemically induced; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology; D012701:Serotonin / Q000494:pharmacology; D012893:Sleep Wake Disorders / Q000139:chemically induced; D013997:Time Factors; D014439:Tyramine / Q000494:pharmacology
D007210:Indoleacetic Acids; D008333:Mandelic Acids; D008996:Monoamine Oxidase Inhibitors; D012701:Serotonin; D005664:Furazolidone; D006493:Heparin; D006631:Amine Oxidase (Copper-Containing); D014439:Tyramine
Hemmung der Monoaminoxydase und Diaminoxydase durch Furazolidon (Furoxon). Pharmakologische und biochemische Untersuchungen am Menschen.